|Bid||10.73 x 800|
|Ask||10.95 x 800|
|Day's range||10.48 - 10.86|
|52-week range||7.61 - 19.99|
|Beta (5Y monthly)||2.03|
|PE ratio (TTM)||N/A|
|Earnings date||21 Feb 2023 - 27 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||16.70|
The mean of analysts' price targets for BioCryst (BCRX) points to a 47.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
BioCryst (BCRX) down as it drops the development of BCX9930, which was being evaluated for PNH.
Participating with me today are CEO, Joh Stonehouse; CFO, Anthony Doyle; chief commercial officer, Charlie Gayer; and chief R&D officer, Dr. New patient starts are consistent with previous quarters, discontinuations appear to have stabilized, and we are investing more to keep this momentum going.